Stimulants

Adlon Therapeutics L.P. Announces Publication of Data from Adhansia XR® (methylphenidate HCl) Extended-Release Capsules CII Studies Examining Sleep Quality Outcomes in CNS Drugs

Monday, June 14, 2021 - 2:23pm

The studies evaluated the effect of Adhansia XR on sleep in adults with Attention-Deficit/Hyperactivity Disorder (ADHD).

Key Points: 
  • The studies evaluated the effect of Adhansia XR on sleep in adults with Attention-Deficit/Hyperactivity Disorder (ADHD).
  • The most common sleep-related adverse events (AEs) in the double-blind study were headache (Adhansia XR, 17.5%; placebo, 11.5%), insomnia (Adhansia XR, 15.8%; placebo, 3.8%) and decreased appetite (Adhansia XR, 11.1%; placebo, 2.6%) for all doses combined.
  • Adhansia XR capsules contain identical beads which are formulated using the proprietary smart design MLR (Multi-Layer Release) technology.
  • Adhansia XR is contraindicated in patients with a known hypersensitivity to methylphenidate or other components of Adhansia XR.

Clean Remedies Highlights Two Energy Boosting CBD Infused Products

Friday, June 11, 2021 - 1:38pm

Clean Remedies has Organic Sour CBD Gummies and CBD Pouches .

Key Points: 
  • Clean Remedies has Organic Sour CBD Gummies and CBD Pouches .
  • For those looking for an oral fixation without the use of tobacco or nicotine products, Clean Remedies CBD Pouches can be a friendly alternative.
  • Both items in Clean Remedies' energy-boost CBD product line can help people reinvigorate their daily routine.
  • Using all-natural ingredients, CBD Power Pouches and CBD Sour Gummies can help you get through the day without that caffeine burnout.

Rritual Superfoods Announces May Purchase Orders

Thursday, June 10, 2021 - 8:05am

VANCOUVER, BC, June 10, 2021 /PRNewswire/ - Rritual Superfoods Inc. ("Rritual" or the"Company") (CSE: RSF)(FSE: 0RW)(OTC: RRSFF)is pleasedto announce that the Company hasreceived purchase orders totaling CAD$306,000 in the last week of May, with goods now shippingto customers.

Key Points: 
  • VANCOUVER, BC, June 10, 2021 /PRNewswire/ - Rritual Superfoods Inc. ("Rritual" or the"Company") (CSE: RSF)(FSE: 0RW)(OTC: RRSFF)is pleasedto announce that the Company hasreceived purchase orders totaling CAD$306,000 in the last week of May, with goods now shippingto customers.
  • "We are extremely excited to have had such a strong launch in our first month of full-scale commercial operations," said Rritual CEO, Mr. David Kerbel.
  • The Rritual Sales Team is in active discussion with a number of target retailers and will provide updates as new retail accounts are onboarded.
  • Rritual product offerings are all USDA-certified organic and are a caffeine-free option that can be mixed with other beverages or enjoyed by itself.

 Jazz Pharmaceuticals Presents 18 Abstracts in Sleep Medicine at SLEEP 2021

Wednesday, June 9, 2021 - 12:45pm

Abuse or misuse of illegal GHB alone or with other drugs that cause changes in alertness (or consciousness) has caused serious side effects.

Key Points: 
  • Abuse or misuse of illegal GHB alone or with other drugs that cause changes in alertness (or consciousness) has caused serious side effects.
  • Call your doctor right away if you or your child has any of these serious side effects.
  • In 2014, Jazz Pharmaceuticals acquired a license to develop and commercialize solriamfetol from Aerial Biopharma LLC.
  • Jazz Pharmaceuticals has worldwide development, manufacturing, and commercialization rights to solriamfetol, excluding certain jurisdictions in Asia.

RespireRx Pharmaceuticals Inc. to Present in June 2021 Access China Biotech Virtual Investor Conference

Tuesday, June 8, 2021 - 11:20pm

Glen Rock, N.J., June 08, 2021 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB Market: RSPI) (RespireRx or the Company), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, is pleased to announce that the Companys senior management will participate in the following virtual investor conference in June 2021:

Key Points: 
  • Glen Rock, N.J., June 08, 2021 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB Market: RSPI) (RespireRx or the Company), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, is pleased to announce that the Companys senior management will participate in the following virtual investor conference in June 2021:
    Access China Biotech 2021 Digital (June 9-14, 2021)
    The Access China Biotech Forumis a quarterly corporate access event series between China and Western biopharma.
  • We believe that the medical and patient community are in clear agreement that there is desperate need for improved antiepileptic drugs.
  • From our AMPAkine platform, our lead clinical compounds, CX717 and CX1739, have successfully completed multiple Phase 1 safety trials.
  • At present, the major pharmacotherapies available for ADHD are made up of two types of drugs.

2021 Global Methylamine Hydrobromide (CAS 6876-37-5) Market Research Report - Downstream Industry Trends - ResearchAndMarkets.com

Tuesday, June 8, 2021 - 3:09pm

The "Methylamine hydrobromide (CAS 6876-37-5) Global Market Research Report 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Methylamine hydrobromide (CAS 6876-37-5) Global Market Research Report 2021" report has been added to ResearchAndMarkets.com's offering.
  • This global report is a result of industry experts' diligent work on researching the world market of Methylamine hydrobromide.
  • The Methylamine hydrobromide global market report key points:
    The first chapter introduces the product (composition, structure, hazards, storage, toxicological & ecological information, etc.).
  • The fifth chapter deals with Methylamine hydrobromide market trends and forecast, distinguish Methylamine hydrobromide manufacturers and suppliers.

Why the North America Psychedelic Drugs Market is Expected to Grow With the Fastest CAGR for Next Several Years

Tuesday, June 8, 2021 - 1:45pm

Psychedelic drugs have the ability to change or enhance the sensory perceptions, thought processes, energy levels and have also been reported to facilitate spiritual experiences.

Key Points: 
  • Psychedelic drugs have the ability to change or enhance the sensory perceptions, thought processes, energy levels and have also been reported to facilitate spiritual experiences.
  • Psychedelic drugs can be categorized into empathogens and dissociative drugs (such as PCP) and serotonergic (classic hallucinogens) such as LSD.
  • A r eport from Data Bridge Market Research projected that the psychedelic drugs market is expected to gain market growth in the forecast period of 2021 to 2028.
  • Data Bridge Market Research analyses that the market is growing with a CAGR of 11.5% in the forecast period of 2021 to 2028 and is expected to reach USD 6,433.94 Million by 2028.

Rritual Superfoods Surpasses Full Year 2021 USA Retail Distribution Targets

Tuesday, June 8, 2021 - 8:05am

Company Leadership Revising Targets to Spur Accelerated Growth Trajectory and Timeline, Aiming for 6000 Stores & 20,000 Points of Distribution

Key Points: 
  • Company Leadership Revising Targets to Spur Accelerated Growth Trajectory and Timeline, Aiming for 6000 Stores & 20,000 Points of Distribution
    VANCOUVER, BC, June 8, 2021 /PRNewswire/ -Rritual Superfoods Inc. ("Rritual" or the"Company") (CSE: RSF)(FSE: 0RW)(OTC: RRSFF)is excitedto announce that the Company has surpassed its retail distribution targets for the end of 2021, exceeding 2400 retail locations and 10,000 points of distribution within the first half of the year.
  • "We set aggressive targets coming into this year, and I am extremely proud of our team and highly encouraged by thecommitmentwe have seen from retailers tothe Rritual Superfoods brand and product line as we have surpassed those targets in a matter of months," said Rritual CEO, Mr. David Kerbel.
  • The Company's product line is being embraced by consumers,with initial sell through with key retail partners triggering new purchase orders and expansion of retail locations.
  • Rritual product offerings are all USDA-certified organic and are a caffeine-free option that can be mixed with other beverages or enjoyed by itself.

Lennham Pharmaceuticals Announces Topline Results from Pharmacokinetic Study of d9-Caffeine Versus Caffeine

Monday, June 7, 2021 - 3:03pm

Lennham Pharmaceuticals today announced topline results of the first ever human study of d9-caffeine.

Key Points: 
  • Lennham Pharmaceuticals today announced topline results of the first ever human study of d9-caffeine.
  • The study was conducted to compare the single-dose pharmacokinetics of caffeine versus d9-caffeine and their corresponding metabolites in healthy adult volunteers.
  • Unlabeled caffeine or d9-caffeine at two dose levels were administered with blood samples collected before and up to 48 hours after administration.
  • The effects of caffeine on drowsiness in patients with narcolepsy: a double-blind randomized controlled pilot study.

KemPharm Executives to Participate in Panel Discussions During Upcoming June 2021 Conferences

Thursday, June 3, 2021 - 12:30pm

KemPharms prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, or ADHD, stimulant use disorder (SUD) and CNS rare diseases, including idiopathic hypersomnia (IH).

Key Points: 
  • KemPharms prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, or ADHD, stimulant use disorder (SUD) and CNS rare diseases, including idiopathic hypersomnia (IH).
  • KemPharms lead clinical development candidate for the treatment of SUD, KP879, is based on its prodrug of d-methylphenidate, known as serdexmethylphenidate (SDX).
  • In addition, KemPharm has received FDA approval for AZSTARYSTM, a new once-daily treatment for ADHD in patents age six years and older, and for APADAZ, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen.
  • For more information on KemPharm and its pipeline of prodrug product candidates visit www.kempharm.com or connect with us on Twitter , LinkedIn , Facebook and YouTube .